Drug Profile
ACC 002
Alternative Names: ACC002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Elan Corporation; Wyeth
- Developer JANSSEN Alzheimer Immunotherapy; Pfizer
- Class Alzheimer vaccines; Peptide fragments; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Alzheimer's-disease in USA (IM)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 17 Sep 2009 Elan's Alzheimer's Immunotherapy Programme has been acquired by JANSSEN Alzheimer Immunotherapy